Nebius (NASDAQ: NBIS) has announced the winners of its first AI Discovery Awards, providing over $850,000 in GPU cloud and inferencing credits to innovative healthcare and life sciences companies. The competition selected four main winners from 257 global applications, each receiving $100,000 in GPU credits. Winners include Ataraxis AI (cancer treatment prediction with 30% higher accuracy), Aikium (targeting undruggable proteins), Transcripta Bio (transcriptomic atlas with billion gene responses), and MetaSight Diagnostics (population-scale disease diagnostics). Second and third-place winners received $50,000 and $30,000 respectively, while seven honorable mentions in each category got $5,000 in credits. The awards were judged by 19 experts from leading organizations including AstraZeneca BioPharma, NVIDIA, Monte Rosa Therapeutics, and Utrecht University.
Nebius (NASDAQ: NBIS) ha annunciato i vincitori dei suoi primi AI Discovery Awards, assegnando oltre 850.000 dollari in crediti GPU cloud e inferenza a societ脿 innovative nel settore sanitario e delle scienze della vita. La competizione ha selezionato quattro vincitori principali tra 257 candidature globali, ciascuno ricevendo 100.000 dollari in crediti GPU. I vincitori sono Ataraxis AI (predizione del trattamento del cancro con una precisione superiore del 30%), Aikium (mirato a proteine non farmacologiche), Transcripta Bio (atlante trascrittomico con miliardi di risposte geniche) e MetaSight Diagnostics (diagnostica delle malattie su scala di popolazione). I secondi e terzi classificati hanno ricevuto rispettivamente 50.000 e 30.000 dollari, mentre sette menzioni d'onore per categoria hanno ottenuto 5.000 dollari in crediti. La giuria era composta da 19 esperti di organizzazioni leader come AstraZeneca BioPharma, NVIDIA, Monte Rosa Therapeutics e l'Universit脿 di Utrecht.
Nebius (NASDAQ: NBIS) ha anunciado a los ganadores de sus primeros AI Discovery Awards, otorgando m谩s de 850,000 d贸lares en cr茅ditos de GPU en la nube y de inferencia a empresas innovadoras en el sector de la salud y las ciencias de la vida. La competencia seleccion贸 a cuatro ganadores principales entre 257 aplicaciones globales, cada uno recibiendo 100,000 d贸lares en cr茅ditos de GPU. Los ganadores incluyen a Ataraxis AI (predicci贸n del tratamiento del c谩ncer con un 30% m谩s de precisi贸n), Aikium (enfocado en prote铆nas no tratables con f谩rmacos), Transcripta Bio (atlas transcript贸mico con miles de millones de respuestas gen茅ticas) y MetaSight Diagnostics (diagn贸stico de enfermedades a escala poblacional). Los segundos y terceros lugares recibieron 50,000 y 30,000 d贸lares respectivamente, mientras que siete menciones honor铆ficas en cada categor铆a obtuvieron 5,000 d贸lares en cr茅ditos. Los premios fueron evaluados por 19 expertos de organizaciones l铆deres como AstraZeneca BioPharma, NVIDIA, Monte Rosa Therapeutics y la Universidad de Utrecht.
Nebius (NASDAQ : NBIS) a annonc茅 les laur茅ats de ses premiers AI Discovery Awards, attribuant plus de 850 000 dollars en cr茅dits GPU cloud et inf茅rence 脿 des entreprises innovantes dans le domaine de la sant茅 et des sciences de la vie. Le concours a s茅lectionn茅 quatre grands gagnants parmi 257 candidatures mondiales, chacun recevant 100 000 dollars en cr茅dits GPU. Les gagnants incluent Ataraxis AI (pr茅diction du traitement du cancer avec une pr茅cision accrue de 30 %), Aikium (ciblant les prot茅ines difficiles 脿 traiter), Transcripta Bio (atlas transcriptomique avec des milliards de r茅ponses g茅niques) et MetaSight Diagnostics (diagnostics de maladies 脿 l鈥櫭ヽhelle de la population). Les deuxi猫me et troisi猫me places ont re莽u respectivement 50 000 et 30 000 dollars, tandis que sept mentions honorables par cat茅gorie ont obtenu 5 000 dollars en cr茅dits. Le jury 茅tait compos茅 de 19 experts issus d鈥檕rganisations de premier plan telles qu鈥橝straZeneca BioPharma, NVIDIA, Monte Rosa Therapeutics et l鈥橴niversit茅 d鈥橴trecht.
Nebius (NASDAQ: NBIS) hat die Gewinner seiner ersten AI Discovery Awards bekannt gegeben und dabei 眉ber 850.000 US-Dollar an GPU-Cloud- und Inferenzguthaben an innovative Unternehmen im Gesundheits- und Lebenswissenschaftsbereich vergeben. Aus 257 globalen Bewerbungen wurden vier Hauptgewinner ausgew盲hlt, die jeweils 100.000 US-Dollar an GPU-Guthaben erhielten. Zu den Gewinnern geh枚ren Ataraxis AI (Krebsbehandlungsprognosen mit 30 % h枚herer Genauigkeit), Aikium (Fokussierung auf nicht medikament枚s behandelbare Proteine), Transcripta Bio (transkriptomischer Atlas mit Milliarden von Genantworten) und MetaSight Diagnostics (bev枚lkerungsweite Krankheitsdiagnostik). Die Zweit- und Drittplatzierten erhielten jeweils 50.000 bzw. 30.000 US-Dollar, w盲hrend sieben Ehrenpreise pro Kategorie mit 5.000 US-Dollar an Credits dotiert wurden. Die Jury bestand aus 19 Experten f眉hrender Organisationen wie AstraZeneca BioPharma, NVIDIA, Monte Rosa Therapeutics und der Universit盲t Utrecht.
Positive
Significant financial support with over $850,000 in GPU credits to advance healthcare AI innovation
Strong validation process with 19 independent judges from leading organizations
Winners demonstrated concrete results: Ataraxis AI achieved 30% higher accuracy in cancer prediction
Large-scale participation with 257 global applications showing program's reach
Negative
None.
Full-stack AI infrastructure provider backs pioneering companies in biotech, drug discovery, genomics and multiomics, and healthcare diagnostics with GPU cloud and inferencing credits totalling over $850,000.
Amsterdam, Netherlands--(Newsfile Corp. - June 23, 2025) - Nebius (NASDAQ: NBIS) has named the winners of its inaugural AI Discovery Awards, awarding top prizes of $100,000 in GPU credits each to four companies pioneering AI breakthroughs in cancer prediction, protein targeting, transcriptomic mapping, and precision diagnostics.
The winners, selected from 257 global applications by a panel of 19 independent judges from leading biotech, pharma, research and venture capital organizations, represent validated AI solutions with clear paths to market impact:
Biotechnology: - Cancer treatment prediction platform achieved 30% higher accuracy than standard genomic tests in clinical validation across 7,500 patients from 15 institutions. The Kestrel foundation model, trained on hundreds of millions of pathology images, helps oncologists determine whether aggressive treatments like chemotherapy are necessary.
Drug Discovery: - Targets "undruggable" proteins comprising half the human proteome using its Yotta-ML² platform. The company has secured partnerships with four organizations, including three top cancer hospitals, based on successful GPCR proof-of-concept work.
Genomics and Multiomics: - Built a high-resolution transcriptomic atlas containing over a billion gene responses to power AI models predicting biological responses from drug molecules. Recently partnered with Microsoft Research to identify new disease-gene associations.
HealthTech: - Pioneers population-scale disease diagnostics through advanced blood testing, creating the world's largest blood molecular database from over 500,000 participants in the Israel Multi-OMICS Screening Trial. Developing screening products for colorectal cancer and metabolic diseases.
"These teams are pushing the frontier of AI in healthcare and life sciences with credible science and clear paths to market," said Arkady Volozh, founder and CEO of Nebius. "We're proud to help them turn research into real-world impact."
Held for the first time this year, the Nebius AI Discovery Awards connect promising companies leveraging AI in healthcare and life sciences with the computational infrastructure and expertise needed to scale their innovations.
Category winners receive $100,000 in GPU credits for Nebius AI Cloud, with second- and third-placed companies receiving $50,000 and $30,000, respectively, as well as other benefits including mentorship and networking support.
A further seven "honorable mentions" in each category received $5,000 in GPU cloud credits. All participants in the AI Discovery Awards were also granted inferencing credits for Nebius AI Studio.
"These companies represent meaningful progress in applying AI to healthcare's most challenging problems," said Dr. Ilya Burkov, Global Head of Healthcare & Life Sciences Growth at Nebius. "From targeting previously undruggable proteins to predicting cancer treatment outcomes with unprecedented accuracy, these teams are building tools that will directly impact patient care and health outcomes."
2025 Nebius AI Discovery Awards winners
Biotechnology
Drug Discovery
Genomics & Multiomics
HealthTech
1st
Ataraxis AI
Aikium
Transcripta Bio
MetaSight Diagnostics
2nd
Feel Therapeutics
Serna Bio
Converge Bio
Slingshot AI
3rd
Nostics
Leash Bio
Infinnimune
iSono Health
The AI Discovery Awards were evaluated by 19 independent judges from leading pharmaceutical, biotechnology, research and healthcare organizations including AstraZeneca BioPharma, NVIDIA, Monte Rosa Therapeutics and Utrecht University.
More information about the Nebius AI Discovery Awards - including all shortlisted companies in each category, qualification criteria and a full jury list - can be found on Nebius's website at
About Nebius
Nebius is a technology company building full-stack infrastructure to service the explosive growth of the global AI industry, including large-scale GPU clusters, an AI-native cloud platform, and tools and services for developers. Headquartered in Amsterdam and listed on Nasdaq, the Company has a global footprint with R&D hubs across Europe, North America and Israel.
Nebius's AI Cloud has been built from the ground up for intensive AI workloads. With proprietary software and hardware designed in-house, Nebius gives AI builders the compute, storage, managed services and tools they need to build, tune and run their models.
To view the source version of this press release, please visit
FAQ
What is the Nebius AI Discovery Awards program and how much funding does it provide?
The Nebius AI Discovery Awards is an inaugural program providing over $850,000 in GPU cloud and inferencing credits to companies innovating in healthcare and life sciences, with top winners receiving $100,000 each in GPU credits.
Who are the main winners of the 2025 Nebius AI Discovery Awards?
The main winners are Ataraxis AI (Biotechnology), Aikium (Drug Discovery), Transcripta Bio (Genomics & Multiomics), and MetaSight Diagnostics (HealthTech), each receiving $100,000 in GPU credits.
What breakthrough did Ataraxis AI achieve in cancer treatment prediction?
Ataraxis AI's platform achieved 30% higher accuracy than standard genomic tests in clinical validation across 7,500 patients from 15 institutions using their Kestrel foundation model.
How many applications did NBIS receive for the AI Discovery Awards?
Nebius received 257 global applications for the AI Discovery Awards, which were evaluated by 19 independent judges from leading pharmaceutical, biotechnology, research and healthcare organizations.
What is the selection process for the Nebius AI Discovery Awards?
Applications were evaluated by 19 independent judges from organizations like AstraZeneca BioPharma, NVIDIA, Monte Rosa Therapeutics, and Utrecht University, focusing on validated AI solutions with clear paths to market impact.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
